Cited by 398Biosensors and Analytical DetectionMicrofluidic and Capillary Electrophoresis ApplicationsAdvanced biosensing and bioanalysis techniques

Advancing the speed, sensitivity and accuracy of biomolecular detection using multi-length-scale engineering

Open access
Kelley, Shana O., Mirkin, Chad A., Walt, David R., Ismagilov, Rustem F., Toner, Mehmet, Sargent, Edward H.·2014·Nature Nanotechnology

Abstract

Rapid progress in identifying disease biomarkers has increased the importance of creating high-performance detection technologies. Over the last decade, the design of many detection platforms has focused on either the nano or micro length scale. Here, we review recent strategies that combine nano- and microscale materials and devices to produce large improvements in detection sensitivity, speed and accuracy, allowing previously undetectable biomarkers to be identified in clinical samples. Microsensors that incorporate nanoscale features can now rapidly detect disease-related nucleic acids expressed in patient samples. New microdevices that separate large clinical samples into nanocompartments allow precise quantitation of analytes, and microfluidic systems that utilize nanoscale binding events can detect rare cancer cells in the bloodstream more accurately than before. These advances will lead to faster and more reliable clinical diagnostic devices.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/nnano.2014.261

Cites

101 of 101 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • The functionalized NPs possess unique advantages over antibody-based platforms: comparable size and diffusion kinetics to proteins, high surface area per volume and high number of flexible binding sites, and inexpensive, simple, fast, scalable synthesis with minimal batch-to-batch variability.

    “These results highlight the unique advantages that these functionalized NPs possess for protein enrichment over antibody-based platforms: (a) comparable size and diffusion kinetics to proteins, promoting effective capture of low-abundance proteins within complex mixtures20,47,48; (b) high surface area per volume and high number of flexible binding sites, contributing to high ligand density and”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

1 of the 102 references couldn’t be matched to a known paper.

Cited by

Sorted by citations

Authors
Kelley, S. O., Mirkin, C. A., Walt, D. R., Ismagilov, R. F., Toner, M., & Sargent, E. H.
Affiliations
  • University of Toronto (CA)
  • Northwestern University (US)
  • Tufts University (US)
  • California Institute of Technology (US)
  • Harvard University (US)
Corresponding author
Kelley, Shana O.
Venue
Nature Nanotechnology
Published
2014-12
Volume
9
Issue
12
Pages
969-980
ISSN
  • 1748-3387 (ISSN-L)
  • 1748-3395
OpenAlex
W2082607189
Cited by
398
References
102
Citations by year
2026: 11 · 2025: 22 · 2024: 23 · 2023: 26 · 2022: 43 · 2021: 24 · 2020: 44 · 2019: 38 · 2018: 48 · 2017: 42 · 2016: 40 · 2015: 37
FWCI
3.39
Type
journal article
Language
en
Open access
Locations
  • Nature Nanotechnology (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
  • CaltechAUTHORS (California Institute of Technology) (submittedVersion)
Funders
  • National Science Foundation
  • U.S. Department of Defense (W81XWH1110814, W81XWH-11-1-, W81XWH, BC100510)
  • Prostate Cancer Foundation
  • Genome Canada
  • National Institutes of Health (W81XWH)
  • Defense Advanced Research Projects Agency (HR0011-11-2-0006)
  • Advanced Research Projects Agency
  • Canadian Institutes of Health Research
  • National Institute of Biomedical Imaging and Bioengineering (R01EB012946, P41EB002503)
Topics
  • Physical Sciences › Engineering › Biomedical Engineering › Biosensors and Analytical Detection
  • Physical Sciences › Engineering › Biomedical Engineering › Microfluidic and Capillary Electrophoresis Applications
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Advanced biosensing and bioanalysis techniques
Keywords
biomolecule detection, disease biomarkers, nucleic acid detection, microsensors, nanocompartments, microfluidics, clinical diagnostics, detection sensitivity, sample separation
MeSH terms
Humans, Neoplasms, Biomarkers, Tumor, Biosensing Techniques, Nanotechnology

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review